^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Peripheral T-cell Lymphoma
    Regimen:GVD (gemcitabine + pegylated liposomal doxorubicin + vinorelbine tartrate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Peripheral T-Cell Lymphoma...Combination regimen...GVD (gemcitabine, vinorelbine, liposomal doxorubicin) Second-line therapy and subsequent therapy for AITL, INCLUDING NODAL PTCL, TFH, and FTCL and ALCL….Intention to proceed to transplant: GVD (gemcitabine, vinorelbine, liposomal doxorubicin) added as a category 2A